Suppr超能文献

满足勃起功能障碍患者未满足的需求:局部治疗的叙述性综述

Addressing unmet needs for patients with erectile dysfunction: a narrative review of topical therapies.

作者信息

Brock Gerald B, Hellstrom Wayne J G, Giraldi Annamaria, Honig Stanton

机构信息

Department of Surgery, Division of Urology, Western University, London, ON, N6A 4V2, Canada.

Tulane University School of Medicine Department of Urology, New Orleans, LA 70112, United States.

出版信息

Sex Med. 2025 May 12;13(2):qfaf021. doi: 10.1093/sexmed/qfaf021. eCollection 2025 Apr.

Abstract

BACKGROUND

Treatment of patients with erectile dysfunction (ED) was revolutionized by the development and approval of phosphodiesterase type 5 inhibitors (PDE5is), which have been repeatedly shown to be safe and effective in men with this condition. However, some patients do not respond to these agents and others may prefer an alternative therapy.

AIM

The objective of this paper is to evaluate topical therapies for ED used in clinical studies, either as single agents or in combination with a PDE5i, and consequently determine which topical therapies meet the criteria of an 'ideal medication for ED.'

METHODS

The PubMed database was searched to identify clinical studies of topical agents that have been evaluated in men with ED. This review was supplemented by a search of presentations at the 2024 annual meetings of the American Urological Association and Sexual Medicine Society of North America.

RESULTS

The literature review and subsequent screening resulted in 39 clinical studies and 5 meeting abstracts for review. The studies demonstrated efficacy for intraurethral and topical alprostadil, topical prostaglandin E ethyl ester, nitric oxide donors, testosterone (in selected patients), and a non-medicated hydro-alcoholic gel. The studies reviewed also demonstrated a significant benefit of adding topical alprostadil to therapy in patients with inadequate responses to PDE5is. An effective topical therapy delivered to its site of action with a rapid onset could improve patients' and partners' satisfaction with and acceptance of treatment. These actions have been demonstrated by a new over-the-counter agent, MED3000, authorized by the United States Food and Drug Administration, and for topical alprostadil, which is available with a prescription in the European Union.

CLINICAL TRANSLATION

The availability of safe and effective topical ED therapy is an important addition to current treatment options for men with this condition.

STRENGTHS AND LIMITATIONS

This study provides results from a comprehensive search strategy by including a wide range of search criteria. However, the heterogeneity of studies evaluated creates difficulties in directly comparing results from different studies.

CONCLUSION

The results of this analysis show that current topical therapies can provide statistically and clinically significant improvements in erectile function in men with ED and may provide an effective alternative to PDE5i in men who require or prefer an alternative therapy.

摘要

背景

5型磷酸二酯酶抑制剂(PDE5i)的研发和获批彻底改变了勃起功能障碍(ED)患者的治疗方式,多次研究表明其对患有该疾病的男性安全有效。然而,一些患者对这些药物无反应,其他患者可能更喜欢替代疗法。

目的

本文的目的是评估在临床研究中用于治疗ED的局部疗法,这些疗法既可以作为单一药物,也可以与PDE5i联合使用,从而确定哪些局部疗法符合“ED理想药物”的标准。

方法

检索PubMed数据库,以识别在ED男性中评估过的局部药物的临床研究。通过检索美国泌尿外科学会和北美性医学协会2024年年会的报告对本综述进行补充。

结果

文献综述及后续筛选得到39项临床研究和5篇会议摘要以供审查。研究表明尿道内和局部使用前列地尔、局部使用前列腺素E乙酯、一氧化氮供体、睾酮(特定患者)以及一种不含药物的水醇凝胶均有效。所审查的研究还表明,对于对PDE5i反应不足的患者,在治疗中添加局部用前列地尔有显著益处。一种起效迅速且能作用于作用部位的有效局部疗法可以提高患者及其伴侣对治疗的满意度和接受度。美国食品药品监督管理局批准的一种新型非处方药物MED3000以及欧盟可凭处方获得的局部用前列地尔均已证明了这些作用。

临床转化

安全有效的局部ED疗法的出现是目前该疾病男性患者治疗选择的重要补充。

优点和局限性

本研究通过纳入广泛的搜索标准,提供了全面搜索策略的结果。然而,所评估研究的异质性使得直接比较不同研究的结果存在困难。

结论

该分析结果表明,目前的局部疗法可在统计学和临床上显著改善ED男性的勃起功能,对于需要或更喜欢替代疗法的男性,可能是PDE5i的有效替代方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05bc/12066416/2fa388e9db76/qfaf021f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验